ChemRar Ventures

ChemRar Ventures is a Russian venture capital firm specializing in investments within the pharmaceutical and biotechnology sectors. The firm is part of the ChemRar Group, a conglomerate that unites research, manufacturing, and investment companies dedicated to the development and commercialization of innovative medicines, diagnostics, and treatments for life-threatening diseases both in Russia and internationally. ChemRar Ventures manages a diversified portfolio of investments in innovative biotechnological and biopharmaceutical companies, aiming to advance healthcare solutions and improve patient outcomes. The firm's investment strategy encompasses various stages of company development, including seed, early stage, Series A, Series B, growth, late stage, and pre-IPO rounds. ChemRar Ventures focuses on a wide geographical area, with investments spanning Russia, the United States, the European Union, China, India, Brazil, Japan, South Korea, Canada, Australia, Mexico, South Africa, Turkey, Saudi Arabia, Argentina, the United Kingdom, France, Germany, Italy, and Spain. This broad geographical focus allows the firm to tap into diverse markets and identify promising opportunities in the global pharmaceutical and biotechnology landscape. ChemRar Ventures has a history of active involvement in the development of antiviral drugs, notably collaborating with the Russian Direct Investment Fund (RDIF) to produce Avifavir, the first favipiravir-based drug approved for the treatment of COVID-19. This partnership underscores the firm's commitment to addressing global health challenges through innovative pharmaceutical solutions. By leveraging its extensive network and expertise, ChemRar Ventures continues to support the growth and success of its portfolio companies, contributing to advancements in medical treatments and therapies worldwide.

Innovative biotechnological and biopharmaceutical companies, Companies in seed to pre-IPO stages, Companies operating in Russia and internationally